Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CONMED (CNMD)

CONMED adds Kim Kelderman, Bio-Techne CEO, to its board of directors

Neutral Impact 2 of 5 leadership Written later

CONMED Corporation's Board appointed Kim Kelderman as an independent non-employee director effective immediately, on September 8, 2025. He currently serves as President, Chief Executive Officer and a board member of Bio-Techne, and joins the Corporate Governance and Nominating and Strategy Committees.

Key points

  • Appointed to the Board on September 8, 2025, effective immediately, with seats on the Corporate Governance and Nominating Committee and the Strategy Committee.
  • Board determined he is independent under New York Stock Exchange requirements.
  • Received a prorated annual director equity grant valued at approximately $134,766, comprising 500 restricted stock units and options on 6,227 shares, vesting in full on September 8, 2026.
  • Has been President and CEO of Bio-Techne (NASDAQ: TECH) since February 2024.

The filing

CompanyCONMED (CNMD)
Form8-K, current report
Filed with the SECSep 9, 2025, 4:11 PM ET
Accession number0001174947-25-001185

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.